Interim safety analysis of a phase III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: The AIO-sto-0210 FLOT4 study.
Claudia Pauligk
No relevant relationships to disclose
Johannes Meiler
No relevant relationships to disclose
Ralf Dieter Hofheinz
No relevant relationships to disclose
Hans-Georg Kopp
No relevant relationships to disclose
Frank Mayer
No relevant relationships to disclose
Harald Schmalenberg
No relevant relationships to disclose
Kim Luley
No relevant relationships to disclose
Georg Martin Haag
No relevant relationships to disclose
Wolff H. Schmiegel
Consultant or Advisory Role - Amgen (U); Apceth (U); AstraZeneca (U); Merck (U); Roche (U)
Honoraria - Dentsches Ärzteblatt; Deutschlanfunk DLF; Elsevier; Springer; Westdeutscher Rundfunk; Zweites deutsches Fernsehen
Nils Homann
No relevant relationships to disclose
Stephan Probst
No relevant relationships to disclose
Michael Koenigsmann
No relevant relationships to disclose
Nicole Prasnikar
No relevant relationships to disclose
Jorg Trojan
No relevant relationships to disclose
Matthias Egger
No relevant relationships to disclose
Rolf Mahlberg
No relevant relationships to disclose
Michael Heike
No relevant relationships to disclose
Andrea Tannapfel
No relevant relationships to disclose
Elke Jäger
No relevant relationships to disclose
Salah-Eddin Al-Batran
Research Funding - Sanofi